Monday, 16 March 2026
PERSPECTA
News from every angle
All
World
Politics
Business
Technology
Finance
Science
Health
Sport
Culture
Opinion
Environment
← Back to headlines
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference
15 Mar, 21:33 — 15 Mar, 21:33
Post
Share
Copy link
Embed
Sources
Sort: Relevance
Sort: Latest
Sort: Bias (L→R)
Sort: Bias (R→L)
Sort: Factuality
left
center
right
Showing 1 of 1 sources
Yahoo
Mostly Factual
3h ago
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference
Read full article →
Something wrong with this story? Report an issue
Related Stories
Teen pregnancies on the rise again
just now
JOHESU backs FETHI new CMD, seeks improved healthcare
just now
People turn to private health care to beat NHS waits, says watchdog
28m ago
82-year-old Car Driver Injured in Accident is Flown to Hospital
51m ago
Monday, 16 March 2026
Explore
Log in
Sign up
PERSPECTA
News from every angle
